Rchr
J-GLOBAL ID：200901052140726425   Update date: Apr. 08, 2024

Iida Shinsuke

イイダ シンスケ | Iida Shinsuke
Affiliation and department：
Nagoya City University Institute of Medical and Pharmaceutical Sciences, Department of Hematology and Oncology

About Nagoya City University Institute of Medical and Pharmaceutical Sciences, Department of Hematology and Oncology


Job title： Professor
Homepage URL  (1)： http://ncu-ketsuekishuyo.jp
Research field  (1)： Hematology and oncology
Research keywords  (4)： 分子標的療法 ,  白血病 ,  骨髄腫 ,  リンパ腫
Research theme for competitive and other funds  (14)：
  • 2020 - 2023 Exploratory study to find predictive genomic biomarkers using liquid biopsy in multiple myeloma
  • 2020 - 2023 エンハンサープロファイリングによる造血器腫瘍の分子病態理解と治療法の開発
  • 2016 - 2020 Identification of blood biomarkers predicting clinical efficacy of molecular targeting agents in multiple myeloma
  • 2008 - 2010 Identification of effective supportive care for cancer patients undergoing chemotherapy on evidence-based QOL assessment
  • 2005 - 2009 The scientific clinical study of antibody therapy
Show all
Papers (163)：
  • Yasunori Kogure, Hiroshi Handa, Yuta Ito, Masaki Ri, Yuichi Horigome, Masaki Iino, Yoriko Harazaki, Takahiro Kobayashi, Masahiro Abe, Tadao Ishida, et al. ctDNA improves prognostic prediction in relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone. Blood. 2024
  • Keiichiro Fujii, Atsushi Inagaki, Ayako Masaki, Mariko Sugiura, Tomotaka Suzuki, Takashi Ishida, Shigeru Kusumoto, Shinsuke Iida, Hiroshi Inagaki. Nomogram for predicting survival of patients with diffuse large B-cell lymphoma. Annals of hematology. 2024
  • Kentaro Hirade, Shigeru Kusumoto, Hiroya Hashimoto, Kazuhide Shiraga, Shinya Hagiwara, Kana Oiwa, Tomotaka Suzuki, Shiori Kinoshita, Masaki Ri, Hirokazu Komatsu, et al. Low-dose fluconazole as a useful and safe prophylactic option in patients receiving allogeneic hematopoietic stem cell transplantation. Cancer medicine. 2024
  • Hiroaki Hiramatsu, Rui Yokomori, Liu Shengyi, Norio Tanaka, Seiichi Mori, Kazuma Kiyotani, Osamu Gotoh, Shigeru Kusumoto, Nobuaki Nakano, Youko Suehiro, et al. Clinical landscape of TP73 structural variants in ATL patients. Leukemia. 2023
  • 海老名 徹, 鈴木 智貴, 西垂水 希美, 近藤 明希, 中西 陽子, 加藤 佑希康, 松永 尚大, 丸茂 義晃, 浅野 有彩, 木下 史緒理, et al. 骨髄腫治療における、有害事象によるカルフィルゾミブ早期中止. 日本血液学会学術集会. 2023. 85回. 642-642
ｍore...
MISC (65)：
  • Stella Amanda, Tze King Tan, Shinsuke Iida, Takaomi Sanda. Lineage- and Stage-Specific Oncogenicity of IRF4. Experimental Hematology. 2022. 114. 9-17
  • 尾崎 修治, 半田 寛, 小磯 博美, 齋藤 貴之, 角南 一貴, 石田 禎夫, 鈴木 憲史, 成田 朋子, 飯田 真介, 中村 裕一, et al. 多発性骨髄腫の継続・維持療法の有効性に関する傾向スコアマッチング解析(Propensity-score matched analysis of the efficacy of maintenance or continuous therapy on multiple myeloma). International Journal of Myeloma. 2021. 11. 2. 96-96
  • 金森 貴之, 飯田 真介. 【血液疾患におけるゲノム解析研究の進歩とその臨床応用】多発性骨髄腫における網羅的ゲノム解析とその臨床応用. 血液内科. 2020. 80. 3. 364-368
  • 保仙直毅, 吉原哲, 高松博幸, 李政樹, 永田泰之, 小杉浩史, 下村良充, 花村一朗, 藤重夫, 皆内康一郎, et al. 多発性骨髄腫における活性型インテグリンβ7の発現の解析. 日本血液学会学術集会抄録(Web). 2020. 82nd
  • Ken Ohmachi, Tomohiro Kinoshita, Kensei Tobinai, Gakuto Ogawa, Tomonori Mizutani, Nobuhiko Yamauchi, Noriko Fukuhara, Toshiki Uchida, Kazuhito Yamamoto, Kana Miyazaki, et al. Randomized Phase II/III Study of Standard R-CHOP Versus CHOP Combined with Dose-Dense Weekly Rituximab (RW-CHOP) for Previously Untreated DLBCL: JCOG0601. BLOOD. 2018. 132
ｍore...
Education (1)：
  • - 1987 Nagoya City University Faculty of Medicine
Professional career (1)：
  • 名古屋市立大学医学部/博士(医学)
Work history (1)：
  • 1991~1994 Visiting scientist, Aichi Cancer Center Research Institute, Nagoya, Japan1994~1997 Visiting scientist/Postdoctoral fellow, Department of Pathology, Columbia University, New York, NY, USA
Association Membership(s) (8)：
European Hematology Association ,  American Society of Hematology ,  日本臨床腫瘍学会 ,  日本造血細胞移植学会 ,  日本癌学会 ,  日本血液学会 ,  日本内科学会 ,  Japanese Society of Myeloma
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page

TOP

BOTTOM